This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INTS Intensity Therapeutics (INTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesOwnershipShort InterestTrendsBuy This Stock About Intensity Therapeutics Stock (NASDAQ:INTS) 30 days 90 days 365 days Advanced Chart Get Intensity Therapeutics alerts:Sign Up Key Stats Today's Range$2.36▼$2.7950-Day Range N/A52-Week Range$0.26▼$5.10Volume73,559 shsAverage Volume431,470 shsMarket Capitalization$8.12 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut. Read More Intensity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingIntensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.58% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently increased by 42.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics does not currently pay a dividend.Dividend GrowthIntensity Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.58% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently increased by 42.89%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest6 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.10% of the stock of Intensity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics is held by institutions.Read more about Intensity Therapeutics' insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INTS Stock News HeadlinesIntensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve ...July 2, 2025 | finanznachrichten.deIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) - Seeking AlphaJuly 2, 2025 | seekingalpha.comTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tied to President Trump's Executive Order #14196 could not only rescue Social Security... But also boost benefits by up to 400%, according to legendary investor Louis Navellier.July 10 at 2:00 AM | InvestorPlace (Ad)Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)June 30, 2025 | prnewswire.comINTS - Intensity Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMIntensity Therapeutics announces public offering of common stockJune 13, 2025 | investing.comIntensity Therapeutics, Inc. Announces Pricing of Public OfferingJune 11, 2025 | prnewswire.comIntensity Therapeutics, Inc. Announces Proposed Public Offering of Common StockJune 11, 2025 | prnewswire.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How were Intensity Therapeutics' earnings last quarter? Intensity Therapeutics Inc. (NASDAQ:INTS) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. When did Intensity Therapeutics IPO? Intensity Therapeutics (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share. What other stocks do shareholders of Intensity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings5/13/2025Today7/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Price Target for Intensity Therapeutics$8.50 High Price Target$12.00 Low Price Target$5.00 Potential Upside/Downside+2,659.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-527.85% Return on Assets-276.29% Debt Debt-to-Equity Ratio0.31 Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.62Miscellaneous Outstanding Shares25,070,000Free Float20,786,000Market Cap$7.72 million OptionableNot Optionable Beta3.27 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:INTS) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.